Crossmark

Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis

Crossref DOI link: https://doi.org/10.1038/s41375-018-0262-2

Published Online: 2018-09-28

Published Print: 2019-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Abeykoon, Jithma P.

Zanwar, Saurabh https://orcid.org/0000-0001-5074-8453
Dispenzieri, Angela

Gertz, Morie A.

Leung, Nelson https://orcid.org/0000-0002-5651-1411
Kourelis, Taxiarchis

Gonsalves, Wilson

Muchtar, Eli https://orcid.org/0000-0003-2210-2174
Dingli, David

Lacy, Martha Q.

Hayman, Suzanne R.

Buadi, Francis

Warsame, Rahma

Kyle, Robert A.

Rajkumar, Vincent

Kumar, Shaji https://orcid.org/0000-0001-5392-9284
Kapoor, Prashant
License Information

Text and Data Mining valid from 2018-09-28
More Information

Article History

Received: 26 June 2018

Revised: 15 August 2018

Accepted: 21 August 2018

First Online: 28 September 2018

Compliance with ethical standards

:

: Dr. Gertz has received funding from Amgen, Prothena, Annexon, Appellis, Johnson and Johnson and Celgene. Dr. Dispenzieri has received research funding from Jannsen, Takeda, Celgene, Pfizer, Alnylam, Prothena, and GSK and serves on the advisory board for Takeda and Intellia. Dr. Kumar received research grants for clinical trials from Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, Amgen. Dr. Leung serves on the advisory board for Takeda and Prothena. Dr. Kapoor is principal investigator on studies for which Mayo Clinic receives funding from Takeda, Sanofi, and Amgen. The remaining authors declare no conflicts of interest.